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a b s t r a c t
The role of the thyroid gland in ischemic stroke pathology is not well understood. As thyroid
hormones modulate the extracellular matrix, we explored the possible link between them
and secreted protein acidic and rich in cysteine like 1 (SC1) – one of the extracellular matrix
molecules.
In the 81 patients with acute ischemic stroke, serum SC1 levels were much higher compared
with 30 control subjects: 4.47 vs 2.43 ng/mL (p < 0.001). Serum levels of free thyroxine (fT4) were
higher in stroke subjects compared to those of controls (p = 0.03). In stroke patients, TSH
concentration was lower than in the control group (p = 0.03). SC1 levels positively correlated
with fT4 levels (p = 0.02) and negatively with TSH (p = 0.03) in stroke patients.
Our results conﬁrmed the association between thyroid hormones and SC1 – extracellular
matrix protein.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Recently, the role of the thyroid gland in the pathophysiology
of acute cerebrovascular diseases has been intensively
explored. Clinical studies have demonstrated t that thyroid
hormones, especially low free triiodothyronine (fT3) are
important factors related to ischemic stroke severity and
outcome [1,2]. A few studies have also proved the association
between TSH (thyroid-stimulating hormone), fT3 and clinical
course in subarachnoid hemorrhage [3].* Corresponding author at: Department of Neurology, Poznan University 
E-mail address: wambrosius@ump.edu.pl (W. Ambrosius).
https://doi.org/10.1016/j.pjnns.2018.01.001
0028-3843/© 2018 Polish Neurological Society. Published by Elsevier SThe pathological aspect of thyroid hormones disturbances
in acute stroke is not well understood. It is not surprising given
the very complex interactions between the thyroid gland and
human brain. We know, for a fact, that thyroid hormones
participate in brain connectivity by inﬂuence on neuronal
migration, synaptic plasticity and binding with their receptor
on integrin aVß3 which, in turn, affects a large number of
extracellular matrix proteins [4]. Secreted protein acidic and
rich in cysteine like 1 (SC1) belongs to this family of
extracellular matrix molecules presented in the human brain.of Medical Sciences, ul. Przybyszewskiego 49, 60-355 Poznan, Poland.
p. z o.o. All rights reserved.
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with ischemic stroke severity [5]. It would be interesting if
there is a link between thyroid hormones and extracellular
matrix (ECM) molecules expression in cerebrovascular disease.
Therefore, we investigated the association between TSH, fT3,
fT4 (free thyroxine) and SC1 in ischemic stroke patients.
2. Material and methods
We studied ischemic stroke patients consecutively admitted to
the Department of Neurology and Cerebrovascular Disorders,
within one year of observation. Acute ischemic stroke was
deﬁned according to the World Health Organization criteria. We
excluded patients with clinical conditions with possible
inﬂuence on TSH, fT3, fT4 and SC1 levels, such as: a history
of thyroid gland disease, recent surgery or trauma, renal
insufﬁciency, malignancy, inﬂammatory disease, liver failure or
recent myocardial infarction. Brain imaging (CT or MRI) was
performed routinely within 1 h after admission. Thirty subjects
matched for age with conﬁrmed traditional vascular risk factors
but without stroke in the history comprised the control group.
All study participants gave written, informed consent and the
Ethics Committee of our University approved the study.
Baseline characteristics with following variables were
recorded: gender, age, history of vascular risk factors and also
total cholesterol, HDL cholesterol, triglycerides, white blood
cell count (WBC), TSH, fT4, and fT3. Biochemical tests were
performed in all patients at the admission. SC1 levels were
quantiﬁed by commercially available ELISA (Abcam, Cam-
bridge, UK) from blood samples stored at 80 8C until assay.
2.1. Statistical analysis
Most of the continuous variables had non-normal distribution;
therefore, results are median with interquartile range (IQR).
Categorical variables are presented as counts (with percent-
age). The differences between the study groups were evaluatedTable 1 – The basic characteristics of explored population.
Characteristic Stroke patients (n = 8
Female sex (n) 32 
Mean age (years) 67  14 
Atrial ﬁbrillation, n (%) 28 (34%) 
Hypertension, n (%) 60 (74,1%) 
Diabetes, n (%) 22 (27%) 
History of stroke or TIA, n (%) 25 (30%) 
Coronary heart disease, n (%) 36 (44.4%) 
Current cigarette smoking, n (%) 18 (22,2%) 
Cholesterol (mg/dL) 205 (160–228) 
HDL cholesterol (mg/dL) 47 (39.2–62.1) 
Triglyceride (mg/dL) 121 (99.75–165) 
WBC (109 L–1) 8.48 (7.06–10.71) 
TSH (mIU/mL) 1.16 (0.48–1.85) 
fT4 (pg/mL) 17.6 (15–19.4) 
fT3 (pg/mL) 4.2 (3.27–4.82) 
SC1 (ng/mL) 4.47 (3.34–5.16 
All data are presented as number (with percentage) or median (with inte
WBC: white blood cell count; TSH: thyroid stimulating hormone, fT4: free
NS, nonsigniﬁcant, SC1, secreted protein acidic and rich in cysteine-likeusing Chi-square tests (categorical variables) and Mann–
Whitney tests (continuous variables), as appropriate. Because
distributions of thyroid gland markers levels appeared to be
left-skewed, they were normalized by log-transformation, and
we examined associations between SC1 levels and TSH, fT3,
fT4 with Pearson correlation analysis. A p-value <0.05 was
considered as statistically signiﬁcant.
3. Results
At the end of the recruitment period, 81 out of 260 acute stroke
patients fulﬁlled inclusion and exclusion criteria and were
enrolled in the study. Apart from matching for age the number
of women and men was the same in the control and stroke
patient groups. Table 1 shows the basic characteristics of the
studied population.
In the 81 patients with acute ischemic stroke, serum SC1
levels were much higher compared with 30 control subjects:
4.47 ng/mL (IQR, 3.34–5.16) versus 2.43 ng/mL (IQR, 1.43–3.16)
( p < 0.001). The TSH and fT4 levels were also signiﬁcantly
different between studied groups. In stroke patients TSH
concentration was lower than in the control group: 1.16 mIU/
mL (IQR, 0.48–1.85) versus 1.52 mIU/mL (IQR, 0.92–2.61)
( p = 0.03). Serum levels of fT4 were slightly higher in stroke
subjects when compared to the control group 17.6 pg/mL (IQR,
15–19.4) versus 13.8 pg/mL (IQR, 12.68–17.75) ( p = 0.03).
SC1 levels positively correlated with (logarithmic) fT4
concentration (r = 0.26, p = 0.02) in stroke patients (Fig. 1A).
SC1 levels showed also modest negative correlation with TSH
(r = 0.24, p = 0.03) (Fig. 1B). We did not ﬁnd any association
between fT4 and SC1.
4. Discussion
The present study showed that circulating SC1 levels in
patients with acute ischemic stroke were associated with1) Control group (n = 30) p-value
16 NS
65  9 NS
0 (0%) <0.001
25 (83.3%) NS
9 (30%) NS
0 (0%) <0.001
9 (41.8%) NS
8 (26.6%) NS
193 (152–239) NS
55 (39.2–62.1) 0.09
113 (82–153) NS
5.85 (5.24–6.7) <0.001
1.52 (0.92–2.61) 0.03
13.8 (12.68–17.75) 0.03
4.22 (3.88–4.71) NS
2.43 (1.43–3.16) <0.001
rquartile ranges).
 thyroxine, fT3: free triiodothyronine; HDL: high-density lipoprotein;
 1.
Fig. 1 – Correlations between SC1 and fT4 (A) and TSH (B).
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the control group. SC1 is an anti-adhesive glycoprotein that
belongs to the ECM proteins involved in tissue remodeling [6].
The experimental study revealed that after transient brain
ischemia SC1 is up-regulated in astrocytes [7]. Clinical studies
on the role of SC1 in stroke are spare. As mentioned above,
one study proved that high levels of SC1 were associated with
moderate and severe clinical status of ischemic stroke
patients [5].
A vital source of brain ECM proteins are astrocytes. We
know that these cells are not the simple framework for
neurons organization but act in many crucial processes, like
cerebral blood ﬂow and the glucose homeostasis. A variety of
important functions of reactive astrocytes depend on ECM
delivered by these cells, such as: regulation of cell migration,
survival, differentiation, and axonal pathﬁnding. It was
demonstrated that thyroid hormones (especially T3, the
product of T4 conversion) regulate the expression of ECM
proteins and induce astrocytes to promote neurite outgrowth
in vitro [8]. The favorable effect of T4 treatment on brain
ischemic injury was proved in experimental studies [9]. Thus,
we can speculate that results of our clinical study (especially
the positive correlation between fT4 and SC1) are theadditional input to the hypothesis about the neuroprotective
effect of thyroid hormones in ischemic stroke, via stimulating
acting on ECM proteins. There are few plausible reasons for
observing no association between T3 and SC1.
The classic thyroid hormones signaling pathway involves
T3 binding to nuclear receptors, T4 has a much lower afﬁnity
for them. However, alternative mechanism, called nonge-
nomic or extranuclear, has been recognized and it mainly
involves T4 which interact with mentioned above integrin
aVß3 within the cell membrane. Probably such thyroid
nongenomic action predominates in astrocytes [10].
The major limitation of our report is a low number of
patients which could not allow for multivariate statistical
analysis. However, it is a pilot study, and we treat these
results as preliminary, which is the impulse for conduction
the research on the larger group of patients. It is necessary to
determine the independent nature of our ﬁndings. In
conclusion, our data provide evidence about the association
between fT4 and TSH and SC1 in stroke patients, which could
be a phenomenon encountered in ischemic stroke patho-
physiology.
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